The Cost Effectiveness of Apligraf® Treatment of Diabetic Foot Ulcers

PharmacoEconomics

Volumn 21, Issue 16, 2003, Pages 1171-1183

  Redekop, W Ken ^a   McDonnell, Joseph ^a   Verboom, Paul ^a   Lovas, Kornelia ^b   Kalo, Zoltan ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APLIGRAF; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETIC FOOT; DISEASE SIMULATION; ECONOMIC ASPECT; FOOT AMPUTATION; INTERMETHOD COMPARISON; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; SKIN EXPANSION; TISSUE ENGINEERING; WOUND CARE;

AMBULATORY CARE; AMPUTATION; BACTERIAL INFECTIONS; COLLAGEN; COST-BENEFIT ANALYSIS; DIABETIC FOOT; HUMANS; MARKOV CHAINS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SKIN, ARTIFICIAL; TIME FACTORS; WOUND HEALING;

EID: 0344441848     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321160-00003     Document Type: Article

References (17)

1. Moss SE, Klein R, Klein B. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992; 152: 610-6
2. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998; 176 (2A Suppl.): 5S-10S
3. Reiber G. Diabetic foot care: financial implications and practice guidelines. Diabetes Care 1992; 15 (1 Suppl.): 29-31
4. Apelqvist J, Ragnarson-Tennvall G, Persson U, et al. Diabetic foot ulcers in a multidisciplinary setting: an economic analysis of primary healing and healing with amputation. J Intern Med 1994; 235: 463-71
5. Apelqvist J, Ragnarson-Tennvall G, Larsson J, et al. Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Foot Ankle Int 1995; 16 (7): 388-94
6. Huse DM, Oster G, Killen AR, et al. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989 Nov 17; 262 (19): 2708-13
7. Ollendorf DA, Kotsanos JG, Wishner WJ, et al. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care 1998; 21 (8): 1240-5
8. Apelqvist J, Bakker K, van Houtum WH, et al., editors. International Working Group on the Diabetic Foot. International consensus on the diabetic foot. Maastricht: International Working Group on the Diabetic Foot, 1999
9. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24 (2): 290-5
10. Persson U, Willis M, Ödegaard K, et al. The cost-effectiveness of treating diabetic lower extremity ulcers with Becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health 2000; 3 (1 Suppl.): S39-46
11. Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001; 19 (7): 767-78
12. Wagner Jr FW. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 1981; 2 (2): 54-122
13. Nabuurs M, van den Berg R, Redekop W, et al. Medical consumption and quality of life of diabetic foot patients in comparison to a background population. Diabetologia 2000 Aug; 43 (1 Suppl.): A224
14. van Houtum WH, Lavery LA, Harkless LB. The costs of diabetes-related lower-extremity amputations in the Netherlands. Diabet Med 1995; 12: 777-81
15. van Houtum WH, Lavery LA, Harkless LB. The impact of diabetes-related lower-extremity amputations in the Netherlands. J Diabetes Complications 1996; 10 (6): 325-30
16. Brem H, Balledux J, Bloom T, et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 2000; 135: 627-34
17. Allenet B, Parée F, Lebrun T, et al. Cost-effectiveness modeling of Dermagraft® for the treatment of diabetic foot ulcers in the French context. Diabete Metab 2000; 26 (2): 125-32